Table 3.
Comparison of RESTART and the pooled cohort of OXVASC and LATCH using all follow-up data
| RESTART (all; n=537) | RESTART (without antiplatelet therapy; n=269) | Pooled OXVASC plus LATCH (fulfilling RESTART eligibility criteria;*n=246) | p value | ||
|---|---|---|---|---|---|
| Baseline characteristics | |||||
| Mean age, years | 76 | 76 | 79 | 0·00010 | |
| Sex | |||||
| Male | 360 (67%) | 187 (70%) | 118 (48%) | <0·0001 | |
| Female | 177 (33%) | 82 (30%) | 128 (52%) | .. | |
| Previous hypertension | 401 (75%) | 207 (77%) | 198 (80%) | 0·33 | |
| Previous diabetes | 127 (24%) | 70 (26%) | 42 (17%) | 0·013 | |
| Previous atrial fibrillation | 92 (17%) | 50 (19%) | 130 (53%) | <0·0001 | |
| Lobar ICH location | 332 (62%) | 166 (62%) | 116 (47%)† | 0·00094 | |
| Risk of outcomes | |||||
| Recurrent ICH | |||||
| Number | 35 | 23 | 13 | .. | |
| Rate (95% CI), per 100 patient-years | 3·3 (2·2–4·4)† | 4·4 (2·6–6·1) | 3·5 (1·9–6·0) | 0·52 | |
| Ischaemic stroke | |||||
| Number | 46 | 27 | 13 | .. | |
| Rate (95% CI), per 100 patient-years | 4·4 (3·2–5·7) | 5·3 (3·3–7·2) | 3·4 (1·9–5·9) | 0·19 | |
ICH=intracerebral haemorrhage. OXVASC=Oxford Vascular Study. LATCH=Lothian Audit of the Treatment of Cerebral Haemorrhage.
*
Patients in OXVASC and LATCH taking antithrombotic drugs before ICH for atrial fibrillation, previous transient ischaemic attack, ischaemic stroke, stroke of unknown subtype, peripheral artery disease, or myocardial infarction.
†
Data missing for one patient.